| abstract |
In one embodiment, the layered pharmaceutical formulation comprises two or more pharmaceutical layers and an intermediate layer disposed between the two or more pharmaceutical layers, wherein the intermediate layer is dissolved in vivo, whereby the two or more pharmaceutical The layer is substantially intact. In one embodiment, the active pharmaceutical ingredient of at least one of the pharmaceutical layers is selected from the group consisting of bupropion, jonisamid, naltrexone, topiramate, pentamine, metformin, olanzapine and fluoxetine. |